Antiglycation effect

Antiglycation effect refers to the biological or pharmacological process of inhibiting glycation, a non-enzymatic reaction where reducing sugars bond to proteins, lipids, or nucleic acids (PubMed: 24324367). This reaction sequence, known as the Maillard reaction, results in the formation of advanced glycation end-products (AGEs), which accumulate in tissues and cause structural damage through protein cross-linking (Wikipedia). The accumulation of AGEs is a major driver in the development of diabetic complications, such as nephropathy and retinopathy, as well as atherosclerosis and neurodegenerative disorders like Alzheimer's disease (PubMed: 15307908). Compounds with antiglycation properties, such as aminoguanidine and pyridoxamine, act by scavenging reactive dicarbonyl intermediates like methylglyoxal or by protecting amino groups on proteins from sugar attachment. By reducing the burden of AGEs, these agents help mitigate oxidative stress and chronic inflammation often mediated by the Receptor for Advanced Glycation End-products (RAGE). Consequently, achieving an antiglycation effect is a key therapeutic strategy aimed at slowing disease progression and preserving organ function in metabolic and age-related disorders.

Other names

Inhibition of advanced glycation end-product formationProtein glycation inhibitionNon-enzymatic glycosylation inhibitionAGE inhibition

The antiglycation effect is mediated through the scavenging of alpha-dicarbonyl compounds (reactive precursors to AGEs), chelation of metal ions that catalyze glycoxidation, or competitive binding to lysine and arginine residues on proteins to prevent sugar attachment (PubMed: 11133333).